Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 3

Primer hepatik nöroendokrin tümör: Ameliyat öncesi farklı tanılı 5 olgu

Primary hepatic neuroendocrine tumor: Five cases with different preoperative diagnoses

Pages
272–278
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, primary hepatic neuroendocrine tumors are very rare and asymptomatic tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroendocrine tumors, also known as carcinoid tumors, behave like benign tumors; however, they show the characteristics of carcinoma.
📊
Key Findings & Data:While more than 80% of the neuroendocrine tumors found in the liver are metastatic, primary hepatic neuroendocrine tumors are very rare.
💡
Conclusion & Impact:In conclusion, primary hepatic neuroendocrine tumors are very rare and asymptomatic tumors.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Karsinoid tümör · Nöroendokrin tümörler · Ameliyat öncesi dönem

Abstract

Neuroendocrine tumors, also known as carcinoid tumors, behave like benign tumors; however, they show the characteristics of carcinoma. While more than 80% of the neuroendocrine tumors found in the liver are metastatic, primary hepatic neuroendocrine tumors are very rare. Five patients with hepatic mass who admitted to our clinic between August 2003 and July 2007 were treated surgically. Ultrasonography, computerized tomography and magnetic resonance imaging were performed in all patients. Endoscopy and colonoscopy were conducted to exclude malignancy of other sites. Hepatectomy was carried out in all patients. Diagnosis was confirmed with immunohistochemical examination. The five patients treated surgically were diagnosed as primary hepatic neuroendocrine tumor histopathologically. Abdominal pain was the most common complaint of all patients. Hepatectomy was conducted in all patients due to tumors originating from the liver lobes. Only one patient (Case 2) underwent transarterial chemoembolization before hepatectomy to reduce tumor bleeding. Owing to tumor recurrence on the left lobe of the liver in Case 2, transarterial chemoembolization was performed four years after hepatectomy. R0 resection was achieved in two patients (Cases 1 and 3). In conclusion, primary hepatic neuroendocrine tumors are very rare and asymptomatic tumors. Thus, high-sensitive laboratory and imaging examinations are required. At present, hepatectomy remains the main treatment for primary hepatic neuroendocrine tumor.

Özet

Karsinoid tümör olarakta bilinen nöroendokrin tümörler aslında iyi huylu tümör gibi davranan fakat karsinom karakteri gösteren tümörlerdir. Karaciğerde yerleşmiş olan nöroendokrin tümörlerin %80 kadarı metastatik iken karaciğerin primer nöroendokrin tümörleri oldukça nadir görülür. Karaciğerde kitle tanısı ile Ağustos 2003 – Temmuz 2007 tarihleri arasında kliniğimize başvuran 5 hasta cerrahi yöntem ile tedavi edildi. Ultrasonografi, bilgisayarlı tomografi ve manyetik rezonans görüntüleme tüm hastalar için yapıldı. Diğer malign odakları tespit ve ekarte edebilmek için endoskopi ve kolonoskopi planlandı. Tüm hastalara hepatektomi yapıldı. Histopatolojik tanı immünohistokimyasal yöntem ile doğrulandı. Cerrahi yöntem ile tedavi edilen beş hasta histopatolojik olarak hepatik nöroendokrin tümör tanısı aldı. Karın ağrısı en sık gözlenen şikayet idi. Hepatektomi tümörün yerleşim yerine göre yapıldı. Sadece bir hastaya (olgu 2) hepatektomi öncesi tümörün kanlanmasını azaltmak için transarteryal kemoembolizasyon yapıldı. Aynı hastaya gelişen tümör nüksü nedeniyle hepatektomiden 4 yıl sonra tekar transarteryal kemoembolizasyon işlemi uygulandı. R0 rezeksiyona yalnız iki hastada ulaşıldı (olgu 1 ve 3). Primer hepatik nöroendokrin tümörler çok nadir görülen ve asemptomatik seyreden tümörlerdir. Halen daha yüksek duyarlılıkta labaratuvar ve görüntüleme tetkiklerine ihtiyaç duyulmaktadır. Günümüzde hepatektomi primer hepatik nöroendokrin tümör için hala asıl olan tedavi yöntemidir.

🔖

Cite This Article

YALAV, O., ÜLKÜ, A., AKÇAM, A. T., DEMİRYÜREK, H., DORAN, F. (2012). Primer hepatik nöroendokrin tümör: Ameliyat öncesi farklı tanılı 5 olgu. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 3, 272–278. https://ajindex.com/articles/411105

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813-29
  2. Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240: 117-22
  3. Edmondson H. Tumor of the liver and intrahepatic bile duct. Atlas of tumor pathology, section 7, fascicle 25. Washington, DC: Armed Forces Institute of Pathology, 1958; 105-9
  4. Godwin II JD. Carcinoid tumors. An analysis of 2837 cases. Cancer 1975; 36: 560-9
  5. Williams ED, Sandler M. The classification of carcinoid tumors. Lancet 1963; 1: 238-9
  6. Solcia E, Kloppel G, Sobin LH. WHO histological typing of endocrine tumours. 2nd ed. Berlin: Springer, 2000
  7. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004; 43: 617- 25
  8. Donadon M, Torzilli G, Palmisano A, et al. Liver resection for primary hepatic neuroendocrine tumours: report of three cases and review of the literature. Eur J Surg Oncol 2006; 32: 325-8
  9. Mehta DC, Warner RR, Parnes I, Weiss M. An 18-year follow- up of primary hepatic carcinoid with carcinoid syndrome. J Clin Gastroenterol 1996; 23: 60-2
  10. Kaya G, Pasche C, Osterheld MC, Chaubert P, Fontolliet C. Primary neuroendocrine carcinoma of the liver: an autopsy case. Pathol Int 2001; 51: 874-8
  11. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol 2001; 22: 309-39
  12. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 1967-73
  13. Erikson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000; 62: 33-8. 14. van der Hoef M, Crook DW, Marincek B, Weishaupt D. Primary neuroendocrine tumors of the liver: MRI features in two cases. Abdom Imaging 2004; 29: 77-81
  14. Sippel RS, Chen H. Carcinoid tumors. Surg Oncol Clin N Am 2006; 15: 463-78
  15. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-400
  16. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002; 32: 84-91
  17. Tamm EP, Kim EE, Ng CS. Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21: 409-32
  18. Zhang